Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as tipifarnib (R115777)
Tipifarnib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tipifarnib (R115777) | DRUG | - |
Inclusion Criteria: * Refractory or relapsed Acute myeloid leukemia (AML) * Eastern Cooperative Oncology Group (ECOG) performance of 0-2 * any value of WBC * able to eat food and medication orally * females must use contraception and not be pregnant Exclusion Criteria: * .Not in another study wit...
Tipifarnib is being studied for the treatment of acute myeloid leukemia, also described as nonlymphocytic acute leukemia. It has been evaluated in patients with relapsed or refractory acute myeloid leukemia in a Phase 2 clinical trial. It is an investigational small molecule and is not described as approved for any indication.
Tipifarnib targets the farnesyltransferase enzymes FNTA and FNTB. It acts as an inhibitor of these enzymes. By inhibiting farnesyltransferase, tipifarnib interferes with the prenylation of proteins such as RAS, which is relevant to its investigation in acute myeloid leukemia.
Tipifarnib is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company is responsible for the clinical development of the drug, including the Phase 2 study in acute myeloid leukemia.
Tipifarnib is in Phase 2 clinical development. It has been evaluated in a completed Phase 2 trial in patients with relapsed or refractory acute myeloid leukemia. It is an investigational agent and is not described as approved by the FDA for any indication.
Tipifarnib has been studied in a Phase 2 clinical trial identified as NCT00354146. The trial was titled "A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia." It enrolled 252 patients and has been completed.
Yes, tipifarnib is also known as R115777. The alternative designation R115777 appears in the title of its Phase 2 trial in acute myeloid leukemia, confirming that both names refer to the same investigational small molecule.